These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 20488818)

  • 41. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A.
    Sharifov OF; Nayyar G; Ternovoy VV; Palgunachari MN; Garber DW; Anantharamaiah G; Gupta H
    Innate Immun; 2014 Nov; 20(8):867-80. PubMed ID: 24323453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of HDL mimetic peptide 4F on PON1.
    Vakili L; Hama S; Kim JB; Tien D; Safarpoor S; Ly N; Vakili G; Hough G; Navab M
    Adv Exp Med Biol; 2010; 660():167-72. PubMed ID: 20221879
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.
    De Blasio MJ; Ramalingam A; Cao AH; Prakoso D; Ye JM; Pickering R; Watson AMD; de Haan JB; Kaye DM; Ritchie RH
    Eur J Pharmacol; 2017 Jul; 807():12-20. PubMed ID: 28438648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids.
    Navab M; Ruchala P; Waring AJ; Lehrer RI; Hama S; Hough G; Palgunachari MN; Anantharamaiah GM; Fogelman AM
    J Lipid Res; 2009 Aug; 50(8):1538-47. PubMed ID: 19225094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human apolipoprotein AI mimetic peptides for the treatment of atherosclerosis.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Hough G; Wagner A; Nakamura K; Garber DW; Datta G; Segrest JP; Hama S; Fogelman AM
    Curr Opin Investig Drugs; 2003 Sep; 4(9):1100-4. PubMed ID: 14582455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal.
    Navab M; Anantharamaiah GM; Reddy ST; Van Lenten BJ; Datta G; Garber D; Fogelman AM
    Curr Opin Lipidol; 2004 Dec; 15(6):645-9. PubMed ID: 15529023
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion.
    Chen G; Paka L; Kako Y; Singhal P; Duan W; Pillarisetti S
    J Biol Chem; 2001 Dec; 276(52):49142-7. PubMed ID: 11579084
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
    Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism.
    Ikewaki K; Rader DJ; Zech LA; Brewer HB
    J Lipid Res; 1994 Oct; 35(10):1809-19. PubMed ID: 7852858
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux.
    Lee M; Calabresi L; Chiesa G; Franceschini G; Kovanen PT
    Arterioscler Thromb Vasc Biol; 2002 Sep; 22(9):1475-81. PubMed ID: 12231569
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice.
    Trapeaux J; Busseuil D; Shi Y; Nobari S; Shustik D; Mecteau M; El-Hamamsy I; Lebel M; Mongrain R; Rhéaume E; Tardif JC
    Br J Pharmacol; 2013 Aug; 169(7):1587-99. PubMed ID: 23638718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention.
    Navab M; Anantharamaiah GM; Reddy ST; Fogelman AM
    Nat Clin Pract Cardiovasc Med; 2006 Oct; 3(10):540-7. PubMed ID: 16990839
    [TBL] [Abstract][Full Text] [Related]  

  • 53. L-4F alters hyperlipidemic (but not healthy) mouse plasma to reduce platelet aggregation.
    Buga GM; Navab M; Imaizumi S; Reddy ST; Yekta B; Hough G; Chanslor S; Anantharamaiah GM; Fogelman AM
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):283-9. PubMed ID: 19965777
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The apolipoprotein A-I mimetic peptide, D-4F, alleviates ox-LDL-induced oxidative stress and promotes endothelial repair through the eNOS/HO-1 pathway.
    Liu D; Ding Z; Wu M; Xu W; Qian M; Du Q; Zhang L; Cui Y; Zheng J; Chang H; Huang C; Lin D; Wang Y
    J Mol Cell Cardiol; 2017 Apr; 105():77-88. PubMed ID: 28274624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet.
    Ou J; Wang J; Xu H; Ou Z; Sorci-Thomas MG; Jones DW; Signorino P; Densmore JC; Kaul S; Oldham KT; Pritchard KA
    Circ Res; 2005 Nov; 97(11):1190-7. PubMed ID: 16224061
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
    Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice.
    Navab M; Hama S; Hough G; Fogelman AM
    Circulation; 2003 Oct; 108(14):1735-9. PubMed ID: 14504179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice.
    Tomiyama-Hanayama M; Rakugi H; Kohara M; Mima T; Adachi Y; Ohishi M; Katsuya T; Hoshida Y; Aozasa K; Ogihara T; Nishimoto N
    Am J Physiol Renal Physiol; 2009 Sep; 297(3):F679-84. PubMed ID: 19570877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.
    Escolà-Gil JC; Julve J; Marzal-Casacuberta A; Ordóñez-Llanos J; González-Sastre F; Blanco-Vaca F
    J Lipid Res; 2000 Aug; 41(8):1328-38. PubMed ID: 10946021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. APOA-1Milano muteins, orally delivered via genetically modified rice, show anti-atherogenic and anti-inflammatory properties in vitro and in Apoe
    Romano G; Reggi S; Kutryb-Zajac B; Facoetti A; Chisci E; Pettinato M; Giuffrè MR; Vecchio F; Leoni S; De Giorgi M; Avezza F; Cadamuro M; Crippa L; Leone BE; Lavitrano M; Rivolta I; Barisani D; Smolenski RT; Giovannoni R
    Int J Cardiol; 2018 Nov; 271():233-239. PubMed ID: 29907443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.